At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 9 enrolled
Drug / intervention
tigecyclinedrug
Likely dose
tigecycline 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-label Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects With Community-acquired Pneumonia
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Dec 17, 2007·Updated Jun 3, 2011
In Brief
A Phase 3 clinical trial evaluating tigecycline for Community-Acquired Infections. Completed, enrolled 9 participants across 9 sites.
Detailed Summary
To purpose of this study is to assess the safety and tolerability of intravenous (IV) tigecycline in hospitalized subjects of Japanese descent with community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-Acquired Infections
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedDec 2007
Primary CompletionMar 2008
TodayJul 2026
First PostedDec 17, 2007
Enrollment StartNov 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.5 years ago
Interventions
tigecyclinedrug
Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days